Cytotoxicity of Bacterial Metabolic Products, including Listeriolysin O, on Leukocyte Targets

Table 4

Survival of PBMC cells of B-CLL patient treated with different concentrations of L.  monocytogenes strain supernatants.

Strain		Supernatant concentrations
		10%	20%	30%	40%	50%
1044	Median	101,0%	93,0%	98,0%	91,0%	84,0%
	P25–P75	100,5–102,0	88,5–94,5	95,5–98,0	90,5–94,5	80,0–92,0
10403S	Median	53,0%	27,0%	12,0%	3,0%	9,0%
	P25–P75	31,0–80,5	16,0–63,5	8,0–38,5	2,0–17,0	7,0–22,0
MAC	Median	71,0%	62,0%	49,0%	23,0%	20,0%
	P25–P75	36,5–83,5	31,0–65,0	24,5–51,0	11,5–38,0	10,0–25,0
1189	Median	49,0%	23,0%	14,0%	11,0%	19,0%
	P25–P75	47,5–72,5	20,5–61,5	13,0–41,5	8,0–30,0	12,0–25,0
1190	Median	98,0%	72,0%	70,0%	23,0%	6,0%
	P25–P75	65,5–98,0	55,0–85,0	48,0–85,0	17,5–60,0	5,5–7,0

Patients were not previously treated for leukemia. Cells were cultured in vitro for 6 days before the experiment. The percent given is that of living cells in the PI assay with different final supernatant concentrations of 10–50%, following incubation for 30 min at 22^°C (median values, P25–P75, 𝑛=3). The incubation medium contained 4% inactivated NCS. The activity of the MAC supernatant was not significantly different than that of supernatants of the 10403S, 1189, and 1190 strains.